SeaLife Pharma was founded in 2008 as a marine biotechnology company. Its core competence is finding and developing new anti-infective agents derived from the ocean. Here, SeaLife Pharma is breaking new ground, using a specially developed method for the selective identification of suitable organisms, with a focus on marine microbes.
SeaLife Pharma’s target markets are manufacturers of antibiotic and antifungal agents in Europe and the USA. Moreover, there is a first definitive success: in laboratory tests, SeaLife Pharma can already manufacture substances that have proved effective against multi-drug-resistant bacterial pathogens.